Comprehensive review of CBD pharmacology for epilepsy, from mechanisms to drug interactions | Research

The takeaway

FDA-approved CBD (Epidiolex) reduces seizures in Dravet and Lennox-Gastaut syndromes at 10-20 mg/kg/day, but its complex pharmacokinetics and interaction with clobazam complicate interpretation of both efficacy and side effects.

Epilepsy patients and families, healthcare professionals, and anyone wanting to understand the science behind FDA-approved CBD.

CBD bioavailability increases 4x with a high-fat meal; ~50% of trial benefit may involve clobazam interaction

What the researchers found

CBD at 10 and 20 mg/kg/day was superior to placebo in reducing drop seizures (LGS) and convulsive seizures (DS) across four RCTs. Oral bioavailability is low but increases fourfold with high-fat meals. About half of trial participants were on clobazam, and CBD increases its active metabolite norclobazam, potentially contributing to both efficacy and adverse effects.

Why it matters

Epidiolex was a landmark FDA approval for a cannabis-derived medicine. This review unpacks the complexity behind the headlines, particularly the clobazam interaction that complicates understanding whether CBD's benefits come from its own effects or from boosting another drug.

The numbers in context

FDA-approved for Dravet and Lennox-Gastaut syndromes (2018). Doses: 10 and 20 mg/kg/day in two divided doses. Bioavailability increases 4x with high-fat meals. ~50% of trial participants on clobazam. Mechanism may involve GPR55 antagonism, TRPV1 desensitization, adenosine reuptake inhibition.

How the study worked

Comprehensive review of CBD pharmacology including mechanism of action, pharmacokinetics, clinical trial results from four randomized controlled trials, drug interactions, and adverse event profiles for epilepsy treatment.

What this study cannot tell us

The exact antiseizure mechanism remains unclear. Most clinical evidence comes from patients on multiple medications, making it hard to isolate CBD's direct contribution. Variable pharmacokinetics (especially food effects) make consistent dosing challenging.

How to read the evidence

Strong: review of four randomized controlled trials plus comprehensive pharmacological analysis.

When this study was published

Published in 2019.

The bigger picture

The clobazam interaction is a critical nuance. If much of CBD's clinical benefit comes from raising norclobazam levels, then CBD may be functioning partly as a pharmacokinetic enhancer rather than a direct anticonvulsant. This distinction matters for understanding how to best use CBD and for whom.

Questions still open

How much of CBD's epilepsy benefit is direct vs. mediated through clobazam interaction? Does efficacy extend to the broader epilepsy population beyond Dravet and LGS? What is the optimal formulation to improve CBD's low oral bioavailability?

Common questions

How does CBD work for epilepsy?

The exact mechanism is unclear but may involve blocking GPR55 receptors, desensitizing TRPV1 channels, and inhibiting adenosine reuptake. A significant drug interaction with clobazam also appears to contribute to its clinical effects in trials.

Why does taking CBD with food matter?

CBD's oral bioavailability increases fourfold when taken with a high-fat meal. This means the same dose can have very different blood levels depending on whether it's taken with or without food, which has important implications for consistent dosing.

Read the original research

Pharmacological and Therapeutic Properties of Cannabidiol for Epilepsy.

Drugs, 79(13), 1435-1454

View on PubMed ↗Publisher’s paper ↗

Citation

Franco, Valentina; Perucca, Emilio. (2019). Pharmacological and Therapeutic Properties of Cannabidiol for Epilepsy.. Drugs, 79(13), 1435-1454. https://doi.org/10.1007/s40265-019-01171-4